684 results on '"Ritter, Gerd"'
Search Results
102. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses
103. Distinct but overlapping T helper epitopes in the 37–58 region of SSX-2
104. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients
105. Evaluation of Mut+ and MutS Pichia pastoris Phenotypes for High Level Extracellular scFv Expression under Feedback Control of the Methanol Concentration
106. Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells
107. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma
108. Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor
109. Sequential Equivalence Checking by Symbolic Simulation
110. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris
111. Real-Time, label-free monitoring of tumor antigen and serum antibody interactions
112. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR
113. Formal Verification of Descriptions with Distinct Order of Memory Operations
114. Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial
115. Monitoring CD4 + T cell responses against viral and tumor antigens using T cells as novel target APC
116. Identification of NY-ESO-1 Epitopes Presented by Human Histocompatibility Antigen (HLA)-DRB4*0101-0103 and Recognized by CD4+ T Lymphocytes of Patients with NY-ESO-1-expressing Melanoma
117. Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
118. The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies
119. Abstract 4716: Targeting specific TGF-β isoforms in combination with radiation therapy leads to differential antitumor effects in mouse models of cancer
120. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
121. Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells
122. Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model
123. Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization
124. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 + cancers
125. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck
126. Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells
127. Abstract 3220: A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR
128. Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies
129. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse
130. 'But Dr. Old, we already have an antibody!' Reflections on Lloyd Old’s 'academic biotech' approach for targeted antibodies
131. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck
132. Erratum: Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy
133. Development of a Transient Mammalian Expression Process for the Production of the Cancer Testis Antigen NY-ESO-1
134. Development of a Transient Mammalian Expression Process for the Production of the Cancer Testis Antigen NY-ESO-1
135. Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1
136. A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy
137. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma
138. Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells
139. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR
140. Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
141. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas
142. Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
143. Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
144. Rebmab200, a Humanized Monoclonal Antibody Targeting the Sodium Phosphate Transporter NaPi2b Displays Strong Immune Mediated Cytotoxicity against Cancer: A Novel Reagent for Targeted Antibody Therapy of Cancer
145. Overcoming regulatory T-cell suppression by a lyophilized preparation ofStreptococcus pyogenes
146. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
147. Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
148. Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
149. Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
150. NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.